Quantitative Systematic Strategies LLC Invests $201,000 in Teladoc Health, Inc. (NYSE:TDOC)

Quantitative Systematic Strategies LLC purchased a new position in Teladoc Health, Inc. (NYSE:TDOC) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 1,211 shares of the health services provider’s stock, valued at approximately $201,000.

Several other institutional investors have also bought and sold shares of the company. ARK Investment Management LLC lifted its position in Teladoc Health by 11.0% in the 2nd quarter. ARK Investment Management LLC now owns 16,016,998 shares of the health services provider’s stock valued at $2,663,467,000 after purchasing an additional 1,592,818 shares during the last quarter. Baillie Gifford & Co. lifted its position in Teladoc Health by 6.0% in the 2nd quarter. Baillie Gifford & Co. now owns 8,417,244 shares of the health services provider’s stock valued at $1,399,704,000 after purchasing an additional 478,165 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its position in Teladoc Health by 27.7% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 6,107,141 shares of the health services provider’s stock valued at $1,015,556,000 after purchasing an additional 1,323,274 shares during the last quarter. Nikko Asset Management Americas Inc. lifted its position in Teladoc Health by 28.0% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 5,690,529 shares of the health services provider’s stock valued at $946,335,000 after purchasing an additional 1,244,967 shares during the last quarter. Finally, Discovery Value Fund lifted its position in Teladoc Health by 9.2% in the 1st quarter. Discovery Value Fund now owns 2,313,347 shares of the health services provider’s stock valued at $420,451,000 after purchasing an additional 195,208 shares during the last quarter. Institutional investors own 79.43% of the company’s stock.

TDOC stock opened at $134.90 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.79 and a current ratio of 4.00. The stock has a market cap of $21.48 billion, a P/E ratio of -23.79 and a beta of 0.24. The firm has a 50 day simple moving average of $144.50 and a 200 day simple moving average of $158.64. Teladoc Health, Inc. has a 52 week low of $129.74 and a 52 week high of $308.00.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Tuesday, July 27th. The health services provider reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.27). The company had revenue of $503.14 million for the quarter, compared to analyst estimates of $499.85 million. Teladoc Health had a negative return on equity of 1.29% and a negative net margin of 46.86%. The business’s revenue for the quarter was up 108.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.34) earnings per share. Sell-side analysts predict that Teladoc Health, Inc. will post -3.53 EPS for the current year.

In other news, CEO Jason N. Gorevic sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 3rd. The stock was sold at an average price of $150.12, for a total value of $1,501,200.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Arnnon Geshuri sold 4,050 shares of the firm’s stock in a transaction dated Thursday, August 26th. The shares were sold at an average price of $143.29, for a total value of $580,324.50. Following the completion of the sale, the insider now directly owns 88,908 shares in the company, valued at $12,739,627.32. The disclosure for this sale can be found here. Insiders sold 19,470 shares of company stock valued at $2,930,104 over the last quarter. Corporate insiders own 6.47% of the company’s stock.

Several analysts recently weighed in on the stock. Cowen cut their price objective on shares of Teladoc Health from $240.00 to $188.00 and set an “outperform” rating on the stock in a research report on Monday, August 9th. Barclays lowered their target price on shares of Teladoc Health from $240.00 to $170.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 28th. BTIG Research lowered their target price on shares of Teladoc Health from $300.00 to $260.00 and set a “buy” rating on the stock in a research note on Wednesday, July 28th. Deutsche Bank Aktiengesellschaft cut shares of Teladoc Health from a “buy” rating to a “hold” rating and lowered their target price for the company from $225.00 to $153.00 in a research note on Wednesday, July 28th. Finally, Craig Hallum lowered their target price on shares of Teladoc Health from $202.00 to $165.00 and set a “hold” rating on the stock in a research note on Wednesday, July 28th. Twelve investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $217.75.

Teladoc Health Company Profile

Teladoc Health, Inc engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure.

Featured Story: Is it Safe to Invest in Commodities?

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.